Pfizer Acquires Treerly and Its Family of Products from Sirio Pharma

Pfizer Inc. has acquired Sirio Pharma Co. Ltd.’s wholly-owned subsidiary, Treerly Health Co., Ltd., and its family of Treerly products.

Treerly is one of the top healthcare brands in China’s retail channel and consists of an extensive portfolio of products uniquely designed to meet women’s nutritional healthcare needs throughout their lives. The Treerly portfolio complements Pfizer Consumer Healthcare’s product portfolio in China and will strengthen its position as a leading provider of over-the-counter (OTC) dietary supplements. Pfizer Consumer Healthcare’s Caltrate® calcium supplements and Centrum® multivitamin supplements are among the top three brands in the OTC vitamin and minerals supplement category in China.

Sirio Pharma is a private, closely-held contract manufacturing company in China that produces dietary supplements and drugs. Sirio is currently a qualified third-party supplier to Pfizer Consumer Healthcare. Under the terms of the agreement, Sirio will continue to supply the high-quality Treerly family of products to Pfizer Consumer Healthcare.

The acquisition of the Treerly brand and its family of products will enhance the portfolio of dietary supplements we offer to our retail customers in China and will enable us to help more consumers improve their health and well-being
said Keith Choy, regional president, Asia Pacific, Pfizer Consumer Healthcare. “The addition of the Treerly products will also make it possible to leverage our existing sales and marketing capabilities and be more efficient in launching future innovations for consumers in China,” he said.